---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000072"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:38:33.948328+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded

## Summary
- Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.
- Interest rate of one-month SOFR + 6.50%, with a 2.50% SOFR floor; matures July 31, 2030.
- Proceeds for working capital, general corporate purposes, and refinancing existing ABL facility.
- Credit facility is secured by substantially all assets of Myriad and its subsidiaries.
- Company now has access to over $200M in capital (including cash) to support growth strategy.

## SEC filing metadata
- accession: 0000899923-25-000072
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000072/0000899923-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000072/mygn-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000072
- JSON: https://secwatch.observer/filing/0000899923-25-000072.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000072.txt

## Key facts
- Debt Financings
  MYRIAD GENETICS INC incurred credit facility of $200 million term loan credit facility with OrbiMed Royalty & Credit Opportunities IV, LP at the greater of the one-month SOFR Rate and 2.50% plus 6.50% maturing July 31, 2030.
  - Instrument: credit facility
  - Principal: $200 million term loan credit facility
  - Counterparty: OrbiMed Royalty & Credit Opportunities IV, LP
  - Rate: the greater of the one-month SOFR Rate and 2.50% plus 6.50%
  - Maturity: July 31, 2030
  - Event: incurrence
  source text: On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum principal amount of $125 million, which amount was funded on the Closing Date, and delayed draw term loans (the “Delayed Draw Loans” and together with the Initial Loan, the “Loans”) at the election of the Company on or prior to June 30, 2027, in a maximum principal amount of $75 million (the “Credit Facility”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992325000072/0000899923-25-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.